These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32522587)

  • 1. Knockout mouse models are predictive of malformations or embryo-fetal death in drug safety evaluations.
    Catlin NR; Stethem CM; Bowman CJ; Campion SN; Nowland WS; Cappon GD
    Reprod Toxicol; 2020 Sep; 96():11-16. PubMed ID: 32522587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockout mouse models are predictive of malformations or embryo-fetal death in drug safety evaluations.
    Catlin NR; Stethem C; Bowman CJ; Campion SN; Nowland WS; Cappon GD
    Reprod Toxicol; 2021 Jan; 99():138-143. PubMed ID: 33065206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2016 and 2017.
    Barrow P
    Reprod Toxicol; 2018 Sep; 80():117-125. PubMed ID: 29660390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictivity of preliminary embryo-fetal development (EFD) studies: results of a retrospective survey in Japanese pharmaceutical companies.
    Okahashi N; Ikeda T; Kai S; Komatsu S; Matsui H; Yamashita Y; Yamamoto K; Sagami F
    J Toxicol Sci; 2010 Feb; 35(1):21-31. PubMed ID: 20118621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of embryo-fetal developmental toxicity studies performed for recent FDA-approved pharmaceuticals.
    Ishihara-Hattori K; Barrow P
    Reprod Toxicol; 2016 Sep; 64():98-104. PubMed ID: 27112525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2018 and 2019.
    Barrow P; Clemann N
    Reprod Toxicol; 2021 Jan; 99():144-151. PubMed ID: 32593570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a new protocol for a zebrafish MEFL (malformation or embryo-fetal lethality) test method that conforms to the ICH S5 (R3) guideline.
    Mori K; Aoki Y; Mikashima F; Maki K; Tanaka T; Hayashi M; Sugimoto W; Ono M; Umekita S; Niino T; Fujiwara M; Ebata T; Hirata H; Kojima H
    J Toxicol Sci; 2024; 49(8):337-348. PubMed ID: 39098043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects.
    Theunissen PT; Beken S; Beyer BK; Breslin WJ; Cappon GD; Chen CL; Chmielewski G; De Schaepdrijver L; Enright B; Foreman JE; Harrouk W; Hew KW; Hoberman AM; Hui JY; Knudsen TB; Laffan SB; Makris SL; Martin M; McNerney ME; Siezen CL; Stanislaus DJ; Stewart J; Thompson KE; Tornesi B; Van der Laan JW; Weinbauer GF; Wood S; Piersma AH
    Crit Rev Toxicol; 2016 Nov; 46(10):900-910. PubMed ID: 27848393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a comparative retrospective analysis of rat and rabbit developmental toxicity studies for pharmaceutical compounds.
    Theunissen PT; Beken S; Cappon GD; Chen C; Hoberman AM; van der Laan JW; Stewart J; Piersma AH
    Reprod Toxicol; 2014 Aug; 47():27-32. PubMed ID: 25517003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of rat and rabbit embryofetal development studies with pharmaceuticals: the added value of a second species.
    Roos P; Anggasta C; Piersma AH; van Meer PJK; Theunissen PT
    Crit Rev Toxicol; 2024 Oct; 54(9):619-633. PubMed ID: 39093553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2020 and 2021.
    Barrow P
    Reprod Toxicol; 2022 Sep; 112():100-108. PubMed ID: 35788364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Embryo-fetal developmental toxicity study design for pharmaceuticals.
    Wise LD; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Lerman SA; Ooshima Y; Stump DG
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):418-28. PubMed ID: 20025038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different embryo-fetal toxicity effects for three VLA-4 antagonists.
    Crofts F; Pino M; DeLise B; Guittin P; Barbellion S; Brunel P; Potdevin S; Bergmann B; Hofmann T; Lerman S; Clark RL
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):55-68. PubMed ID: 15098199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development.
    Burdan F; Szumilo J; Klepacz R
    Reprod Toxicol; 2009 Sep; 28(2):239-44. PubMed ID: 19379806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approach methodologies to confirm developmental toxicity of pharmaceuticals based on weight of evidence.
    Catlin NR; Cappon GD; Davenport SD; Stethem CM; Nowland WS; Campion SN; Bowman CJ
    Reprod Toxicol; 2024 Oct; 129():108686. PubMed ID: 39128486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An assessment of the reliability of 52 enhanced preliminary embryofetal development studies to detect developmental toxicity.
    Barrow P
    Birth Defects Res; 2023 Jan; 115(2):218-223. PubMed ID: 36331145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.
    Patyna S; Haznedar J; Morris D; Freshwater K; Peng G; Sukbuntherng J; Chmielewski G; Matsumoto D
    Birth Defects Res B Dev Reprod Toxicol; 2009 Jun; 86(3):204-13. PubMed ID: 19294680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2022 and 2023.
    Barrow P
    Reprod Toxicol; 2024 Dec; 130():108727. PubMed ID: 39332698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure assessments in reproductive and developmental toxicity testing: An IQ-DruSafe industry survey on current practices and experiences in support of exposure-based high dose selection.
    Andrews PA; McNerney ME; DeGeorge JJ
    Regul Toxicol Pharmacol; 2019 Oct; 107():104413. PubMed ID: 31229519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction to special issue on developmental and reproductive toxicity study designs for pharmaceuticals.
    Wise LD
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):417. PubMed ID: 20025037
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.